TY - JOUR
T1 - Effects of prostaglandin analogues on aqueous humor outflow pathways
AU - Winkler, Nelson S.
AU - Fautsch, Michael P.
PY - 2014/3/1
Y1 - 2014/3/1
N2 - Elevated intraocular pressure (IOP) is the most prevalent risk factor for glaucoma. All treatments, whether surgical or pharmaceutical, are aimed at lowering IOP. Prostaglandin analogues are a first line therapy for glaucoma due to their ability to reduce IOP, once-daily dosing, efficacy, and minimal side-effect profile. Whereas prostaglandin analogues have been known to alter aqueous humor outflow through the unconventional (uveoscleral) pathway, more recent evidence suggests their action also occurs through the conventional (trabecular) pathway. Understanding how prostaglandin analogues successfully lower IOP is important, as this information may lead to the discovery of new molecular targets for future therapeutic intervention. This review explores the current understanding of prostaglandin analogue biology as it pertains to IOP reduction and improved aqueous humor outflow facility.
AB - Elevated intraocular pressure (IOP) is the most prevalent risk factor for glaucoma. All treatments, whether surgical or pharmaceutical, are aimed at lowering IOP. Prostaglandin analogues are a first line therapy for glaucoma due to their ability to reduce IOP, once-daily dosing, efficacy, and minimal side-effect profile. Whereas prostaglandin analogues have been known to alter aqueous humor outflow through the unconventional (uveoscleral) pathway, more recent evidence suggests their action also occurs through the conventional (trabecular) pathway. Understanding how prostaglandin analogues successfully lower IOP is important, as this information may lead to the discovery of new molecular targets for future therapeutic intervention. This review explores the current understanding of prostaglandin analogue biology as it pertains to IOP reduction and improved aqueous humor outflow facility.
UR - http://www.scopus.com/inward/record.url?scp=84898756412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898756412&partnerID=8YFLogxK
U2 - 10.1089/jop.2013.0179
DO - 10.1089/jop.2013.0179
M3 - Review article
C2 - 24359106
AN - SCOPUS:84898756412
SN - 1080-7683
VL - 30
SP - 102
EP - 109
JO - Journal of Ocular Pharmacology and Therapeutics
JF - Journal of Ocular Pharmacology and Therapeutics
IS - 2-3
ER -